|
|
|
| Preparation of non RGD peptide conjugated ultrasmall superparamagnetic iron particles and its targeting effect on human umbilical vein endothelial cells |
|
WANG Xiao-dong1, WU Guo-qiu2, LIU Nai-feng3 |
(1.Department of Cardiology, the Affiliated Hospital of Jiangsu University, Zhenjiang Jiangsu 212001; 2.Center of Clinical Laboratory, Medicine of Zhongda Hospital，Southeast University, Nanjing Jiangsu 210009; 3. Institute of Cardiovascular Disease of Zhongda Hospital, Southeast University, Nanjing Jiangsu 210009, China) |
|
|
|
|
Abstract Objective：To develop an ultrasmall superparamagnetic iron oxide (USPIO) based MR probe containing non RGD peptide (named P1c) and investigate its targeting effect on Human umbilical vein endothelial cells (HUVECs). Methods: To prepare immunologically competent probe， P1c was conjugated with USPIO coated with meso-2,3-dimercaptosuccinic acid(DMSA).Cell counting kit-8 assay was conducted to ascertain the probe＇s effect on the HUVECs＇growth. The USPIO labeled P1c peptide was experimental group, and the USPIO was control group. The solid phase binding assay and Prussian blue staining were employed to evaluate the immunocompetence of P1c-USPIO. The probe＇s cell MR imaging in vitro was performed using HUVECs with high integrin αvβ3 expression. Results: The P1cUSPIO was constructed. The probe had no effect on the growth of HUVECs．The solid phase binding assay and Prussian blue staining showed that the probe could bind with integrin αvβ3 on HUVECs with high specificity. MR cell imaging in vitro demonstrated that at the same mass concentration of iron the T2* value in P1cUSPIO group was much shorter than it in USPIO group．Conclusion: The molecular probe P1c-USPIO could be prepared successfully using chemical cross linking method. The P1c-USPIOs remained their immunocompetence. The probe could specifically bind with HUVECs.
|
|
Received: 25 February 2013
|
|
|
|
| [1]Saraste A, Laitinen I, Weidl E, et al. Diet intervention reduces uptake of αvβ3 integrin-targeted PET tracer 18F-galacto-RGD in mouse atherosclerotic plaques[J]. J Nucl Cardiol, 2012, 19(4):775-784.[2]Laitinen I, Saraste A, Weidl E,et al.Evaluation of alphavbeta3 integrin-targeted positron emission tomography tracer 18F-galacto-RGD for imaging of vascular inflammation in atherosclerotic mice[J]. Circ Cardiovasc Imaging, 2009, 2(4):331-338.[3]Waldeck J, Hager F, Holtke C, et al. Fluorescence reflectance imaging of macrophage-rich atherosclerotic plaques using an alphavbeta3 integrin-targeted fluorochrome[J]. J Nucl Med, 2008, 49(11):1845-1851.[4]Wolf G, Abolmaali N. Preclinical molecular imaging using PET and MRI[J]. Recent Results Cancer Res, 2013, 187:257-310.[5]耿兴东,单秀红,熊非,等.葡萄糖受体介导的肿瘤靶向2-DG超顺磁性氧化铁的制备及体外实验[J].山东医药，2012,52(11):1-4.[6]张伟,蔡亮,陈跃,等.99mTc-Gd-DTPA-DG合成及宫颈癌细胞对其摄取的研究[J]．山东医药，2010, 50(23):17-18．[7]Beer AJ, Schwaiger M. Imaging of integrin alphavbeta3 expression[J]. Cancer Metastasis Rev, 2008, 27(4):631-644.[8]BogdanowichKnipp SJ, Chakrabarti S, Williams TD, et al. Solution stability of linear vs. cyclic RGD peptides[J]. J Pept Res, 1999, 53(5):530-541.[9]AssaMunt N, Jia X, Laakkonen P, et al. Solution structures and integrin binding activities of an RGD peptide with two isomers[J]. Biochemistry,2001, 40(8):2373-2378.[10]罗先富，吴晶涛，胡晓华，等.CD40突变体靶向的MR分子探针制备及体外卵巢癌成像的实验研究\[J\].中华放射学杂志,2012,46(3):264-268.[11]Zhang S, Bian Z, Gu C, et al. Preparation of anti-human cardiac troponin I immunomagnetic nanoparticles and biological activity assays[J]. Colloids Surf B Biointerfaces, 2007, 55(2):143-148.[12]Zhang C, Jugold M, Woenne EC,et al.Specific targeting of tumor angiogenesis by RGD-conjugated ultrasmall superparamagnetic iron oxide particles using a clinical 1.5-T magnetic resonance scanner[J]. Cancer Res, 2007, 67(4):1555-1562. |
| [1] |
. [J]. Journal of Jiangsu University(Medicine Edition), 2017, 27(04): 356-359. |
|
|
|
|
2013, Vol. 23 
